KOSDAQBiotech & Pharma014570

Korean Drug

₩2,840▼ 0.35%2026-11-18 close
Market Cap
₩31.2B
Turnover
₩8,801,100
Volume
3.1K
Shares out.
11M
PER
20.0×
PBR
0.4×
EPS
₩143
Dividend Yield
6.30%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩180 per share · Prices as of the 2026-11-18 close

01

Report overview

Margins recovering, but quarterly net income remains volatile

Korean Drug's revenue has declined for two straight years since 2024, yet operating profit stayed positive in the second and third quarters of 2026. Quarterly net income swings, including a net loss in the second quarter of 2026 despite operating profit, remain the key item to watch.

  1. 1

    Revenue peaked at KRW 81.4 billion in 2023 and fell to KRW 62.5 billion in 2025, the second straight annual decline.

  2. 2

    Operating margin fell from 22.2% in 2023 to 11.1% in 2025. Net income attributable to controlling shareholders turned positive in 2024 and rose 117.4% to KRW 6.51 billion in 2025.

  3. 3

    Operating profit in the second quarter of 2026 was KRW 2.66 billion, up 125.7% from the prior quarter, yet the company posted a net loss attributable to controlling shareholders of KRW 3.44 billion. The third quarter returned to a profit of KRW 1.96 billion.

  4. 4

    In the first half of 2026, CNS products and vitamin and nutritional supplements together accounted for 69.0% of sales, a high level of product concentration.

  5. 5

    In its value-up plan disclosed in March 2026, the company set a target of keeping the payout ratio at about 25% of three-year average net income.

02

Business structure

Korean Drug was founded in 1980 and listed on the KOSDAQ in 2000. It manufactures and sells prescription drugs, over-the-counter drugs and health functional foods, distributing them in Korea and abroad through pharmacy, hospital and clinic sales divisions.

In 2025, vitamin and nutritional supplements accounted for about KRW 23.4 billion (37.4%) of annual sales and central nervous system (CNS) products for about KRW 20.1 billion (32.2%), according to a Pharm News report published on October 16, 2026.

In the first half of 2026, CNS products made up 36.6% of sales (KRW 11.3 billion) and vitamin and nutritional supplements 32.4% (KRW 10.0 billion), a combined share of 69.0%. The flagship CNS product is the Alzheimer-type dementia treatment Neurosept, while Glucom and Q-Up are the main vitamin and supplement products.

Over-the-counter lines such as the cold remedy Haven and the anemia treatment Santamon Plus are also maintained. Seven research teams develop new drugs, generics and health functional foods in parallel.

Among the new drug candidates, a natural-product-derived compound for inflammatory bowel disease was at the preclinical stage before clinical testing as of the 2025 quarterly report.

Because sales are concentrated in the CNS and vitamin groups, changes in prescribing conditions or raw material supply for specific products have a large effect on results. Unlike large biotech companies, the business relies more on sales of established products than on new drug revenue.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩16.5B₩2B12.0%
2025Q4₩18B₩1.9B10.5%
2026Q1₩13.3B₩1.2B8.8%
2026Q2₩17.6B₩2.7B15.1%
2026Q3₩18.3B₩2.3B12.3%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩80B₩14.3B₩11.8B17.9%13.9%11.6%
2023₩81.4B₩18B-₩4.9B22.2%−6.4%16.4%
2024₩73B₩9.1B₩3B12.5%3.8%13.8%
2025₩62.5B₩6.9B₩6.5B11.1%7.8%13.5%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-16

04

Earnings analysis

On a disclosed basis, annual revenue rose from KRW 80 billion in 2022 to KRW 81.4 billion in 2023 (up 1.7% year on year), the peak year. It then fell 10.3% to KRW 73 billion in 2024 and 14.4% to KRW 62.5 billion in 2025, a second consecutive annual decline.

Among 2022 to 2025, 2023 was the largest year and 2025 the smallest. Operating profit rose from KRW 14.3 billion in 2022 to KRW 18 billion in 2023 (up 25.8%), then fell 49.3% to KRW 9.14 billion in 2024 and 24.4% to KRW 6.91 billion in 2025.

Operating margin declined from 17.9% in 2022 and 22.2% in 2023 to 12.5% in 2024 and 11.1% in 2025. Since 2024, operating profit has fallen faster than revenue, showing clear margin pressure.

Net income attributable to controlling shareholders moved from KRW 11.8 billion in 2022 to a net loss of KRW 4.92 billion in 2023, a swing into loss. The 2023 loss came despite positive operating profit, which points to a large effect from non-operating items.

The company returned to a profit of KRW 3 billion in 2024 and rose to KRW 6.51 billion in 2025, up 117.4%. Net income including non-controlling interests was also KRW 6.51 billion in 2025.

Operating cash flow was KRW 5.91 billion in 2022, negative KRW 2 billion in 2023, KRW 4.87 billion in 2024 and KRW 13.1 billion in 2025, the highest of the four years.

Year-end 2025 total equity of KRW 83.1 billion was entirely attributable to controlling shareholders, with total liabilities of KRW 11.2 billion and a debt ratio of 13.5%.

Quarterly revenue went from KRW 16.5 billion in the third quarter of 2025 and KRW 18 billion in the fourth quarter to a low of KRW 13.3 billion in the first quarter of 2026, down 25.9% from the prior quarter.

It then rose to KRW 17.6 billion in the second quarter (up 31.7%) and KRW 18.3 billion in the third quarter (up 11.2% year on year), a two-quarter run of growth.

Operating profit was KRW 1.18 billion in the first quarter of 2026, KRW 2.66 billion in the second and KRW 2.25 billion in the third, positive in each quarter.

Net income attributable to controlling shareholders, however, swung to a net loss of KRW 3.44 billion in the second quarter before returning to a profit of KRW 1.96 billion in the third.

Net income attributable to controlling shareholders over the last four quarters, from the fourth quarter of 2025 to the third quarter of 2026, totaled KRW 1.54 billion. Pharm News cited the cost of sales ratio falling from 56.5% to 53.4% in the first half of 2026 as a driver of margin improvement.

05

Industry analysis

Korean Drug's core CNS franchise is supported by structural demand from population aging. According to a Pharm News report published on October 16, 2026, Korean residents aged 65 and over numbered about 11.13 million in 2026, or 21.6% of the population, and are projected to reach 30% by 2036.

Wise Report's company profile also describes steadily rising demand for prescription drugs driven by population aging and a growing burden of chronic disease. Product groups concentrated on elderly patients, such as dementia treatments, are direct beneficiaries of this demand shift.

The vitamin and supplement segment rests on steady demand in the health functional food market, and over-the-counter products and supplements often depend on pharmacy channels rather than prescriptions.

Long-term demand for prescription drugs is rising, but changes in drug pricing rules and prescribing conditions remain variables for pricing. In cycle terms, aging-related demand is growing gradually, while the company's revenue went through a decline from 2024 and showed quarterly recovery in 2026.

Against competitors, Korean Drug is closer to a mid-sized pharmaceutical company centered on established product sales than to large biotech companies built around new drug development or contract manufacturing.

Compared with larger drugmakers in the sector, its new drug pipeline is centered on preclinical projects, so new drug revenue is likely to be a longer-term contributor. This is a qualitative comparison based on the research stages recorded in the 2025 quarterly report.

06

Outlook

The value-up plan the company disclosed on March 20, 2026 has three elements: keeping the payout ratio at about 25% of three-year average net income, pursuing research on a Pressshot formulation for export to the United States, and pursuing adoption of ISO 37001 anti-bribery management standards.

In the same plan, the company said it qualifies as a high-dividend company. The payout ratio for 2025, the most recent fiscal year, was 29.91%, and the dividend amount for 2025 was about KRW 1.9 billion, up 12.6% from 2024.

At the March 2026 general meeting, shareholders approved the financial statements for the 46th fiscal year (2025) and a year-end dividend on common shares.

On products, Pharm News reported reinforcement of the Salviato Dual Control product based on Gombo-baechu, a product using Ssibi-rum and lactic bacteria for intestinal health that has reached the launch stage, and ongoing efficacy evaluation of Gombo-baechu for bone and joint health.

The company describes this as a strategy of strengthening existing product groups while exploring new natural-product areas. According to the 2025 quarterly report, the new product Neurosept Duo tablet received approval on December 23, 2024 and is contract-manufactured.

Pharm News published an annual earnings estimate that assumes first-half growth continues in the second half, but this estimate rests on the assumptions of the article's authors. Within the material reviewed, no official company guidance for annual revenue or operating profit was found.

The next points to confirm are the annual revenue trend and annual operating margin in the 2026 annual report, and whether growth persists once the 2026 quarterly figures are incorporated into the disclosed results.

07

Valuation

PER
20.0×
PBR
0.4×
ROE
1.9%
EPS
₩143
BPS
₩7,465
Dividend per share
₩180

Valuation can be read along three axes: net assets, earnings and dividends. Total equity of KRW 83.1 billion at the end of 2025 was entirely attributable to controlling shareholders, which keeps the comparison of share price with net assets straightforward.

The price-to-book ratio sits in a range where the share price is well below book value per share, a sizable discount to net assets. Earnings-based multiples require more care.

Net income attributable to controlling shareholders over the last four quarters totaled KRW 1.54 billion, so the price-to-earnings ratio moves sharply with quarterly results.

When operating profit is positive but non-operating items produce a net loss, as in the second quarter of 2026, the meaning of an earnings multiple changes. Net income attributable to controlling shareholders rose 117.4% in 2025, but remains below the 2022 level, so the earnings recovery is still short in duration.

Dividends are tied to earnings through the plan to keep the payout ratio at about 25% of three-year average net income, and the 2025 payout ratio was 29.91%. Dividend yield moves inversely with the share price, so its reading changes with price movements. Taken together, a discount to net assets and a volatile earnings-based multiple exist at the same time.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-16

08

Bull factors

Earnings recovery

Net income attributable to controlling shareholders turned positive in 2024 at KRW 3 billion and rose 117.4% to KRW 6.51 billion in 2025. Quarterly operating profit stayed positive in all three quarters of 2026, at KRW 1.18 billion, KRW 2.66 billion and KRW 2.25 billion. Third-quarter 2026 revenue of KRW 18.3 billion rose 11.2% year on year, so the top line is growing again.

Financial capacity

Total liabilities at the end of 2025 were KRW 11.2 billion and the debt ratio was 13.5%, close to the 11.6% level of 2022. Operating cash flow in 2025 was KRW 13.1 billion, the highest of the four years from 2022 to 2025.

Total equity of KRW 83.1 billion is fully attributable to controlling shareholders, so the capital structure is simple.

Shareholder return plan

In its value-up plan disclosed in March 2026, the company set a target of keeping the payout ratio at about 25% of three-year average net income. The 2025 payout ratio was 29.91%, and the 2025 dividend amount rose 12.6% from 2024. The company said it qualifies as a high-dividend company.

09

Bear factors

Two years of revenue decline

Revenue fell 10.3% to KRW 73 billion in 2024 and 14.4% to KRW 62.5 billion in 2025. Operating margin dropped from 22.2% in 2023 to 11.1% in 2025, about half the level. Operating profit has fallen faster than revenue, so defending margins remains a challenge.

Volatility in quarterly net income

In the second quarter of 2026, operating profit was KRW 2.66 billion, yet net income attributable to controlling shareholders swung to a loss of KRW 3.44 billion. Net income attributable to controlling shareholders over the last four quarters totaled only KRW 1.54 billion.

When quarterly net income moves in a different direction from operating profit, the earnings trend is harder to read.

Product concentration and pipeline

In the first half of 2026, CNS products and vitamins together accounted for 69.0% of sales, so revenue is concentrated in two product groups. The new drug candidates were centered on preclinical stages as of the 2025 quarterly report, so new drug sales will take time to contribute. Developing new drugs requires substantial funding and time.

10

Risk factors

Product concentration risk

Two product groups, CNS and vitamins and supplements, account for most of sales, so changes in prescribing conditions or raw material supply for specific products directly affect company-wide results. Raw material supply issues for a key product were also cited as a variable in the 2024 annual report. With a narrow product range, a supply disruption in one product could lead to a decline in revenue.

Quarterly earnings volatility risk

Quarterly revenue bottomed at KRW 13.3 billion in the first quarter of 2026, and the second quarter showed net income moving against operating profit, with a loss of KRW 3.44 billion attributable to controlling shareholders.

Because non-operating items can strongly affect net income, quarterly earnings are difficult to forecast. With a small earnings base, even minor cost changes weigh heavily on net results.

R&D timeline risk

As of the 2025 quarterly report, the new drug projects for indications such as osteoporosis and inflammatory bowel disease remained at preclinical or early stages.

New drug development outcomes depend heavily on success at each clinical stage, and given the company's research scale, results will take a long time to become visible. Research spending may also weigh on short-term profits.

11

What to watch next

  1. By March 31, 2027

    The 2026 annual report will confirm the annual revenue and operating margin trend. The key question is whether the revenue growth seen in the first three quarters of 2026 carries through the full year.

  2. March 2027 annual general meeting

    The dividend resolution for fiscal 2026 will show whether the plan to keep the payout ratio at about 25% of three-year average net income is being followed.

  3. By May 15, 2027

    The first-quarter 2027 quarterly report will show whether non-operating items and net income attributable to controlling shareholders move in line with operating profit.

  4. During 2027

    Progress on the Pressshot formulation research for export to the United States and any disclosure on ISO 37001 adoption, both included in the value-up plan, will be watched.

12

Overall view

Korean Drug's disclosed results for 2022 to 2025 show revenue falling after peaking in 2023, with operating margin declining from 22.2% to 11.1%. Net income attributable to controlling shareholders swung from a loss in 2023 to a profit in 2024 and recovered to KRW 6.51 billion in 2025.

Quarterly results in 2026 show revenue rising in the second and third quarters and operating profit positive in all three quarters.

However, the second quarter of 2026 included a net loss attributable to controlling shareholders of KRW 3.44 billion, and net income over the last four quarters totaled only KRW 1.54 billion. Products are concentrated in CNS and vitamins and supplements, and the new drug pipeline is centered on preclinical stages.

Factors on the positive side include a debt ratio of 13.5%, operating cash flow of KRW 13.1 billion in 2025 and the plan to keep the payout ratio at about 25%. Factors on the negative side include the revenue decline and volatility in quarterly net income.

The next points to confirm are the annual operating margin in the 2026 annual report and the composition of non-operating items in the first-quarter 2027 report.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. jobkorea.co.kr
  2. pharmnews.com
  3. comp.wisereport.co.kr
  4. comp.wisereport.co.kr
  5. k5.co.kr
  6. saramin.co.kr
  7. m.dailypharm.com
  8. newsthevoice.com
  9. kind.krx.co.kr
  10. kind.krx.co.kr
  11. news.nate.com
  12. anewsa.com
  13. m.news.nate.com
  14. m.news.nate.com
  15. anewsa.com
  16. anewsa.com
  17. anewsa.com
  18. anewsa.com

Report written 2026-11-16 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis